A Phase 2a, Randomized, Double-blind, Placebo-controlled Study To Evaluate Safety And Efficacy Of Pf-06700841 In Subjects With Moderate To Severe Plaque Psoriasis
Phase of Trial: Phase II
Latest Information Update: 12 Apr 2018
At a glance
- Drugs PF 6700841 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Pfizer
- 09 Apr 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 23 Mar 2018 to 1 Mar 2018.
- 05 Mar 2018 Planned primary completion date changed from 23 Mar 2018 to 1 Mar 2018.